Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

David Risinger at Leerink Partners says not only was the market reaction overdone, but that the pullback creates a buying opportunity. While lowering his U.S. Zepbound sales estimates to be more ...

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Zepbound's prescription growth has surged ... adding that the company will watch the market's reaction. Novo's Wegovy was in short supply until late February when U.S. regulators said the shortage ...

Although Novo was first to market with Wegovy and its sister drug Ozempic for diabetes, Lilly has gained the lead in obesity prescriptions with Zepbound. The US company’s diabetes version of the ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Call your doctor right away if you have an allergic reaction to Zepbound. But if you think you’re having a medical emergency, call 911 or your local emergency number. Zepbound comes as a liquid ...

A previous version of this report failed to reflect that the scientific name tirzepatide refers to Zepbound. It has been corrected. A study of two blockbuster weight-loss drugs showed that users ...